WARSAW, Ind.,Feb. 7, 2022/PRNewswire/ --Zimmer Biomet (Formerly Known As Biomet Inc.)Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2021. The Company reported fourth quarter net sales of$2.038 billion, a decreas...
Zimmer Biomet Holdings, Inc. reported financial results for the quarter ended September 30, 2023.
WARSAW, Ind.,Feb. 4, 2020/PRNewswire/ --Zimmer Biomet Holdings, Inc.(NYSE and SIX: ZBH) today reported financial results for the quarter and year endedDecember 31, 2019. The Company reported fourth quarter net sales of$2.126 billion, an increase of 2.6% over the prior year ...
Zimmer Biomet Holdings Inc Competitors - Telecommunications Equipment Company Price USD Returns 1-YEAR RETURNS 5-year Intuitive Surgical Inc ISRG $531.88 61.73% 1.78% GE HealthCare Technologies Inc GEHC $83.37 7.92% - Idexx Laboratories, Inc. IDXX $427.26 21.45% 9.48% Dexcom Inc DXCM $79.35 38....
SOURCE Zimmer Biomet Holdings, Inc. Twitter LinkedIn Facebook Email Print MORE ON THIS TOPIC Genetown The Best Way to Answer Salary Interview Questions June 11, 2024 · 4 min read · Lorenzo Soliman Job Trends Life Sciences R&D, Manufacturing Tal...
ZIMMER BIOMET HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in millions, unaudited) December 31, December 31, 2020 2019 Assets Cash and cash equivalents $ 802.1 $ 617.9 Receivables, net 1,452.7 1,363.9 Inventories 2,450.7 2,385.0 Other current assets 377.8 357.1 Total curren...
ZIMMER BIOMET HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2020 and 2019 (in millions, except per share amounts, unaudited) 2020 2019 Net Sales $ 1,929.3 $ 1,892.4 Cost of products sold, excluding intangible asset amortization ...
Full-year 2020 guidance provided - Company expects 2.5% to 3.5% revenue growth on a reported and constant currency basis
Company Codes:Swiss:ZBH, NYSE:ZBH Twitter LinkedIn Facebook Email Print EarningsHealthcare MORE ON THIS TOPIC Cancer Where Keytruda Failed, Regeneron Touts Phase III Skin Cancer Win for Libtayo January 14, 2025 · 2 min read · Tristan Manalac ...
Second quarter net sales of $1.226 billion decreased 38.3%, and decreased 38.0% on a constant currency basis